Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson’s Disease

Cerebral dopamine neurotrophic factor (CDNF) belongs to a newly discovered family of evolutionarily conserved neurotrophic factors. We demonstrate for the first time a therapeutic effect of CDNF in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of Parkinson’s disease in marmoset monkeys. Furthermore, we tested the impact of high chronic doses of human recombinant CDNF on unlesioned monkeys and analyzed the amino acid sequence of marmoset CDNF. The severity of 6-OHDA lesions and treatment effects were monitored in vivo using 123I-FP-CIT (DaTSCAN) SPECT. Quantitative analysis of 123I-FP-CIT SPECT showed a significant increase of dopamine transporter binding activity in lesioned animals treated with CDNF. Glial cell line-derived neurotrophic factor (GDNF), a well-characterized and potent neurotrophic factor for dopamine neurons, served as a control in a parallel comparison with CDNF. By contrast with CDNF, only single animals responded to the treatment with GDNF, but no statistical difference was observed in the GDNF group. However, increased numbers of tyrosine hydroxylase immunoreactive neurons, observed within the lesioned caudate nucleus of GDNF-treated animals, indicate a strong bioactive potential of GDNF.

[1]  Richard Grondin,et al.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.

[2]  Xiaomin Wang,et al.  AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model , 2013, Experimental Neurology.

[3]  R. Bakay,et al.  Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration , 2002, The Journal of Neuroscience.

[4]  R. Ridley,et al.  Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease , 2005, The Journal of Neuroscience.

[5]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[6]  T. Berger,et al.  Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: Histochemical and neurochemical analysis , 1986, Brain Research.

[7]  P. Permi,et al.  Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) Has a Unique Mechanism to Rescue Apoptotic Neurons* , 2010, The Journal of Biological Chemistry.

[8]  D. Hilt,et al.  Glial cell line–derived neurotrophic factor–levodopa interactions and reduction of side effects in parkinsonian monkeys , 1997, Annals of neurology.

[9]  M. Saarma,et al.  Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease , 2011, Experimental Neurology.

[10]  D. Yin,et al.  Optimized cannula design and placement for convection-enhanced delivery in rat striatum , 2010, Journal of Neuroscience Methods.

[11]  R. M. Lightfoot,et al.  Reprint: Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys , 2007, Toxicologic pathology.

[12]  J. Seibyl,et al.  Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  John L. Hudson,et al.  Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo , 1994, Neuroscience Letters.

[14]  N. Déglon,et al.  Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease , 2004, Neurobiology of Disease.

[15]  Gerda Andringa,et al.  Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease , 2005, NeuroImage.

[16]  J. Hoseki,et al.  ARMET is a soluble ER protein induced by the unfolded protein response via ERSE-II element. , 2007, Cell structure and function.

[17]  W. Oertel,et al.  Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. , 2007, NeuroImage.

[18]  M. Saarma,et al.  Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo , 2007, Nature.

[19]  A. Björklund,et al.  α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons , 2012, Science Translational Medicine.

[20]  Timothy Sendera,et al.  Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.

[21]  Andisheh Eslamboli.  Assessment of GDNF in Primate Models of Parkinson's Disease: Comparison with Human Studies , 2005, Reviews in the neurosciences.

[22]  M. Horne,et al.  Timecourse of striatal re‐innervation following lesions of dopaminergic SNpc neurons of the rat , 2003, The European journal of neuroscience.

[23]  C. Olanow.  Parkinson disease: Gene therapy for Parkinson disease—a hope, or a dream? , 2014, Nature Reviews Neurology.

[24]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[25]  Mark Stacy,et al.  Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.

[26]  Chengqun Huang,et al.  Mesencephalic Astrocyte-derived Neurotrophic Factor Protects the Heart from Ischemic Damage and Is Selectively Secreted upon Sarco/endoplasmic Reticulum Calcium Depletion* , 2012, The Journal of Biological Chemistry.

[27]  M. Almeida,et al.  The Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers* , 2015, The Journal of Biological Chemistry.

[28]  M. Saarma,et al.  MANF is indispensable for the proliferation and survival of pancreatic β cells. , 2014, Cell reports.

[29]  J. Andressoo,et al.  MANF is indispensable for the proliferation and survival of pancreatic beta-cells , 2022 .

[30]  R. Ridley,et al.  Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus) , 2003, Experimental Neurology.

[31]  A. Björklund,et al.  GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. , 2011, Brain : a journal of neurology.

[32]  S. Duty,et al.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease , 2011, British journal of pharmacology.

[33]  R. de la Fuente-Fernández.  Role of DaTSCAN and clinical diagnosis in Parkinson disease , 2012, Neurology.

[34]  R. Ridley,et al.  Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. , 2007, Brain : a journal of neurology.

[35]  M. Horne,et al.  Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys , 2005, Behavioural Brain Research.

[36]  A. Goldman,et al.  The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. , 2009, Protein engineering, design & selection : PEDS.

[37]  B. Hoffer,et al.  CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery after MPTP Treatment in Mice , 2012, Cell transplantation.

[38]  Mart Saarma,et al.  Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin , 2011, The Journal of cell biology.

[39]  Katsuki Nakamura,et al.  Stereotaxic Atlas of the Marmoset Brain , 2010 .

[40]  D. Gash,et al.  GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo , 1995, Brain Research.

[41]  M. Saarma,et al.  Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease , 2009, The Journal of Neuroscience.

[42]  A. C. Cuello,et al.  The brain of the common marmoset (Callithrix jacchus) a stereotaxic atlas H. Stephan,G. Baron &W. K. Schwerdtfeger. 1980. Springer-Verlag, Berlin. 5 figs., 3 tab., 73 plates. V 91 pages. Cloth DM 168,-; approx. US $94.10 , 1981, Neuroscience.

[43]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[44]  Peter J. Belmont,et al.  Mesencephalic Astrocyte-Derived Neurotrophic Factor Is an Ischemia-Inducible Secreted Endoplasmic Reticulum Stress Response Protein in the Heart , 2008, Circulation research.

[45]  J. Kordower,et al.  Trophic factors therapy in Parkinson's disease. , 2009, Progress in brain research.

[46]  K. Bankiewicz,et al.  Image-guided convection-enhanced delivery of GDNF protein into monkey putamen , 2011, NeuroImage.

[47]  S. Fang,et al.  Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. , 2008, Experimental cell research.

[48]  P. Pivirotto,et al.  Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF , 2010, The Journal of Neuroscience.

[49]  M. Saarma,et al.  Characterization of the Structural and Functional Determinants of MANF/CDNF in Drosophila In Vivo Model , 2013, PloS one.

[50]  R. Fuente-Fernández,et al.  Role of DaTSCAN and clinical diagnosis in Parkinson disease , 2012 .

[51]  Y. Agid,et al.  Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra , 1996, Brain Research.

[52]  A. Björklund,et al.  Localized striatal delivery of GDNF as a treatment for Parkinson disease , 2004, Nature Neuroscience.

[53]  M. Saarma,et al.  Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons , 2009, Proceedings of the National Academy of Sciences.

[54]  A. Björklund,et al.  Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System , 2000, The Journal of Neuroscience.

[55]  Zhe-yu Chen,et al.  Intracellular trafficking and secretion of cerebral dopamine neurotrophic factor in neurosecretory cells , 2011, Journal of neurochemistry.

[56]  Dr. Heinz Stephan,et al.  The Brain of the Common Marmoset (Callithrix jacchus) , 1980, Springer Berlin Heidelberg.

[57]  Paul S Larson,et al.  Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Peter Dechent,et al.  Structural and quantitative neuroimaging of the common marmoset monkey using a clinical MRI system , 2013, Journal of Neuroscience Methods.

[59]  P. Pivirotto,et al.  Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. , 2009, Human gene therapy.

[60]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[61]  Robert B. Innis,et al.  Iodine-123-β-CIT and Iodine-123-FPCIT SPECT Measurement of Dopamine Transporters in Healthy Subjects and Parkinson's Patients , 1998 .

[62]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[63]  R. van Kesteren,et al.  Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage , 2016, Neuroscience.

[64]  M. Horne,et al.  Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. , 2008, Brain : a journal of neurology.

[65]  Heidi Phillips,et al.  Heparin Coinfusion during Convection-Enhanced Delivery (CED) Increases the Distribution of the Glial-Derived Neurotrophic Factor (GDNF) Ligand Family in Rat Striatum and Enhances the Pharmacological Activity of Neurturin , 2001, Experimental Neurology.

[66]  G. Donnan,et al.  New dopaminergic neurons in Parkinson's disease striatum , 2000, The Lancet.

[67]  Andreas Schober,et al.  Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP , 2004, Cell and Tissue Research.

[68]  G. Gerhardt,et al.  Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.

[69]  D. Alvarez-Fischer,et al.  Quantitative [123I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease , 2007, NeuroImage.

[70]  A. Björklund,et al.  Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[71]  L. Ruddock,et al.  A molecular specificity code for the three mammalian KDEL receptors , 2007, The Journal of cell biology.

[72]  David I. Smith,et al.  MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. , 2003, Journal of molecular neuroscience : MN.

[73]  H. Saji,et al.  In vivo Imaging of Brain Dopaminergic Neurotransmission System in Small Animals with High-resolution Single Photon Emission Computed Tomography , 2003, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[74]  M. Saarma,et al.  Novel CDNF/MANF family of neurotrophic factors , 2010, Developmental neurobiology.

[75]  Gunther Helms,et al.  Visualizing dopamine transporter integrity with iodine-123-FP-CIT SPECT in combination with high resolution MRI in the brain of the common marmoset monkey , 2012, Journal of Neuroscience Methods.

[76]  A. Lang,et al.  Crossroads in GDNF therapy for Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[77]  R. M. Lightfoot,et al.  Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. , 2007, Toxicologic pathology.

[78]  Yun Wang,et al.  Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) Secretion and Cell Surface Binding Are Modulated by KDEL Receptors* , 2012, The Journal of Biological Chemistry.

[79]  M. Saarma,et al.  Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease , 2013, Brain and behavior.

[80]  P. Voorn,et al.  Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[81]  D. Hilt,et al.  Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.

[82]  Randolph M. Johnson,et al.  Hyperplastic Changes within the Leptomeninges of the Rat and Monkey in Response to Chronic Intracerebroventricular Infusion of Nerve Growth Factor , 1997, Experimental Neurology.

[83]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.